![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (1->4)-beta-D-glucan | multiple interactions | ISO | RGD:1323515 | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of ORC2 mRNA | CTD | PMID:36331819 | (S)-nicotine | increases expression | ISO | RGD:1323514 | 6480464 | Nicotine results in increased expression of ORC2 mRNA | CTD | PMID:16949557 | 2,2',4,4'-Tetrabromodiphenyl ether | affects expression | ISO | RGD:1323515 | 6480464 | 2 more ... | CTD | PMID:30294300 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1323515 | 6480464 | [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of ORC2 mRNA | CTD | PMID:25975270 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of ORC2 mRNA | CTD | PMID:33387578 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ORC2 mRNA | CTD | PMID:34747641 | 2,6-dinitrotoluene | affects expression | EXP | | 6480464 | 2, 6-dinitrotoluene affects the expression of ORC2 mRNA | CTD | PMID:21346803 | 2-amino-2-deoxy-D-glucopyranose | decreases expression | ISO | RGD:1323515 | 6480464 | Glucosamine results in decreased expression of ORC2 mRNA | CTD | PMID:17178593 | 2-methylcholine | affects expression | ISO | RGD:1323514 | 6480464 | beta-methylcholine affects the expression of ORC2 mRNA | CTD | PMID:21179406 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:1323514 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of ORC2 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ORC2 mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | multiple interactions | ISO | RGD:1323514 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of ORC2 mRNA | CTD | PMID:28628672 | 4-hydroxyphenyl retinamide | decreases expression | ISO | RGD:1323515 | 6480464 | Fenretinide results in decreased expression of ORC2 mRNA | CTD | PMID:28973697 | 4-nitrophenol | decreases expression | ISO | RGD:1323515 | 6480464 | 4-nitrophenol results in decreased expression of ORC2 mRNA | CTD | PMID:34673133 | aflatoxin B1 | decreases methylation | ISO | RGD:1323514 | 6480464 | Aflatoxin B1 results in decreased methylation of ORC2 gene | CTD | PMID:27153756 | aldehydo-D-glucosamine | decreases expression | ISO | RGD:1323515 | 6480464 | Glucosamine results in decreased expression of ORC2 mRNA | CTD | PMID:17178593 | all-trans-retinoic acid | decreases expression | ISO | RGD:1323514 | 6480464 | Tretinoin results in decreased expression of ORC2 mRNA | CTD | PMID:15498508 | aristolochic acid A | decreases expression | ISO | RGD:1323514 | 6480464 | aristolochic acid I results in decreased expression of ORC2 mRNA | CTD | PMID:33212167 | Aroclor 1254 | decreases expression | ISO | RGD:1323515 | 6480464 | Chlorodiphenyl (54% Chlorine) results in decreased expression of ORC2 mRNA | CTD | PMID:25270620 | atrazine | increases expression | ISO | RGD:1323514 | 6480464 | Atrazine results in increased expression of ORC2 mRNA | CTD | PMID:22378314 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | RGD:1323514 | 6480464 | 7 more ... | CTD | PMID:20018196, PMID:20382639 | benzo[a]pyrene diol epoxide I | increases expression | ISO | RGD:1323514 | 6480464 | 7 more ... | CTD | PMID:26238291 | beta-D-glucosamine | decreases expression | ISO | RGD:1323515 | 6480464 | Glucosamine results in decreased expression of ORC2 mRNA | CTD | PMID:17178593 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of ORC2 mRNA | CTD | PMID:25181051 | bisphenol A | multiple interactions | ISO | RGD:1323514 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ORC2 mRNA | CTD | PMID:28628672 | bisphenol A | affects methylation | ISO | RGD:1323515 | 6480464 | bisphenol A affects the methylation of ORC2 promoter | CTD | PMID:27334623 | carbon nanotube | increases expression | ISO | RGD:1323515 | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | CGP 52608 | multiple interactions | ISO | RGD:1323514 | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to ORC2 gene] | CTD | PMID:28238834 | coumarin | affects phosphorylation | ISO | RGD:1323514 | 6480464 | coumarin affects the phosphorylation of ORC2 protein | CTD | PMID:35688186 | dexamethasone | multiple interactions | ISO | RGD:1323514 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of ORC2 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ORC2 mRNA | CTD | PMID:28628672 | dibutyl phthalate | decreases expression | ISO | RGD:1323515 | 6480464 | Dibutyl Phthalate results in decreased expression of ORC2 mRNA | CTD | PMID:17361019, PMID:21266533 | dioxygen | multiple interactions | ISO | RGD:1323515 | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of ORC2 mRNA | CTD | PMID:30529165 | doxorubicin | decreases expression | ISO | RGD:1323514 | 6480464 | Doxorubicin results in decreased expression of ORC2 mRNA | CTD | PMID:29803840 | epoxiconazole | affects expression | ISO | RGD:1323515 | 6480464 | epoxiconazole affects the expression of ORC2 mRNA | CTD | PMID:35436446 | ethanol | affects expression | ISO | RGD:1323515 | 6480464 | Ethanol affects the expression of ORC2 mRNA | CTD | PMID:30319688 | ethyl methanesulfonate | decreases expression | ISO | RGD:1323514 | 6480464 | Ethyl Methanesulfonate results in decreased expression of ORC2 mRNA | CTD | PMID:23649840 | formaldehyde | decreases expression | ISO | RGD:1323514 | 6480464 | Formaldehyde results in decreased expression of ORC2 mRNA | CTD | PMID:23649840 | glafenine | increases expression | EXP | | 6480464 | Glafenine results in increased expression of ORC2 mRNA | CTD | PMID:24136188 | Heptachlor epoxide | decreases expression | ISO | RGD:1323515 | 6480464 | Heptachlor Epoxide results in decreased expression of ORC2 mRNA | CTD | PMID:25270620 | indometacin | multiple interactions | ISO | RGD:1323514 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of ORC2 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of ORC2 mRNA | CTD | PMID:28628672 | methyl methanesulfonate | decreases expression | ISO | RGD:1323514 | 6480464 | Methyl Methanesulfonate results in decreased expression of ORC2 mRNA | CTD | PMID:23649840 | nicotine | increases expression | ISO | RGD:1323514 | 6480464 | Nicotine results in increased expression of ORC2 mRNA | CTD | PMID:16949557 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of ORC2 mRNA | CTD | PMID:33387578 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | RGD:1323515 | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of ORC2 mRNA | CTD | PMID:36331819 | progesterone | increases expression | ISO | RGD:1323514 | 6480464 | Progesterone results in increased expression of ORC2 mRNA | CTD | PMID:18497975 | quercetin | decreases expression | ISO | RGD:1323514 | 6480464 | Quercetin results in decreased expression of ORC2 mRNA | CTD | PMID:21632981, PMID:23727915 | resveratrol | multiple interactions | ISO | RGD:1323514 | 6480464 | [Plant Extracts co-treated with Resveratrol] results in increased expression of ORC2 mRNA | CTD | PMID:23557933 | sunitinib | decreases expression | ISO | RGD:1323514 | 6480464 | Sunitinib results in decreased expression of ORC2 mRNA | CTD | PMID:31533062 | tamibarotene | decreases expression | ISO | RGD:1323514 | 6480464 | tamibarotene results in decreased expression of ORC2 mRNA | CTD | PMID:15498508 | thapsigargin | decreases expression | ISO | RGD:1323515 | 6480464 | Thapsigargin results in decreased expression of ORC2 protein | CTD | PMID:24648495 | triptonide | increases expression | ISO | RGD:1323515 | 6480464 | triptonide results in increased expression of ORC2 mRNA | CTD | PMID:33045310 | valproic acid | affects expression | ISO | RGD:1323515 | 6480464 | Valproic Acid affects the expression of ORC2 mRNA | CTD | PMID:17963808 | vinclozolin | increases expression | EXP | | 6480464 | vinclozolin results in increased expression of ORC2 mRNA | CTD | PMID:23034163 | zoledronic acid | decreases expression | ISO | RGD:1323514 | 6480464 | zoledronic acid results in decreased expression of ORC2 protein | CTD | PMID:28871336 | |